Italian AAV biotech closes $65M Series A; GSK's Jemperli nabs priority review in endometrial cancer
06 Jun 2023
Priority Review
AAVantgarde, a Milan-based AAV biotech, has closed a €61 million ($65.1 million) Series A round.
The biotech currently has two AAV platforms, one using DNA recombination and another that trans-splices proteins, with treatment targets in ophthalmology. AAVantgarde is seeking to validate its two lead platforms, tagging the funds for a proof-of-concept study and further development.
“This financing represents a hallmark moment in our mission to help patients and we are excited to work with both our new and founding investors to advance our platforms and pipeline. The completion of this round with such a high-caliber group of global life science investors is a recognition of the significance of AAVantgarde’s unique technology, which will initially be utilized to help patients suffering with the debilitating impact of blindness associated with Usher1B syndrome and Stargardt disease,” CEO Natalia Misciattelli said in a
release
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.